{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-24-000118","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.797237+00:00","generated_at":"2026-05-31T22:52:11.123058+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emergent settles Janssen COVID vaccine manufacturing dispute; receives $50M","bullets":["Janssen will pay Emergent $50M by July 31, 2024 under settlement agreement.","Settlement resolves all claims and arbitration related to MSA for Ad26.COV2-S vaccine.","Parties exchange broad releases covering affiliates, officers, and directors.","Ends previously disclosed arbitration between Emergent and Janssen."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-24-000118","json":"https://secwatch.observer/filing/0001367644-24-000118.json","markdown":"https://secwatch.observer/filing/0001367644-24-000118.md","text":"https://secwatch.observer/filing/0001367644-24-000118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000118/0001367644-24-000118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000118/ebs-20240703.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:52:11.123058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}